[Key takeaway]
The bidding war between Pfizer and Novo Nordisk over Metsera is a sign-post for pharma’s future. It’s not just about acquiring a biotech—it’s about gaining entry into a market of staggering size, controlling supply chains and positioning for the next generation of obesity therapeutics.
A Surprising Swoop into Obesity Drugs
On October 30, 2025, Novo Nordisk launched an unsolicited bid to acquire Metsera, the U.S.-based biotech developing next-generation obesity therapies. The offer valued Metsera at up to approximately US $9 billion, dramatically increasing the stakes of this acquisition race.
Pfizer, which had earlier announced a deal to buy Metsera for around $7.3 billion, found itself suddenly challenged. The Danish company’s counterbid signalled a bold push to defend its dominance in the obesity-therapy space. (Source: Reuters, Oct 31, 2025)

A Legal Battlefield Opens
In response to Novo’s move, Pfizer filed lawsuits accusing Novo and Metsera of anticompetitive conduct, breach of contract and seeking to block the deal through Delaware court. (Source: Reuters, Nov 1, 2025)
However, on November 4, 2025, a Delaware judge ruled that the court need not intervene directly in the bidding war at this stage, signaling the legal fight will unfold but not immediately halt the acquisition process. (Source: Reuters, Nov 5, 2025)
Market Impact & Strategic Stakes
This takeover fight is more than corporate rivalry—it reflects the convergence of three major industry trends:
- The obesity-treatment market (including GLP-1 and other metabolic drugs) is expected to peak at around US $150 billion by 2035. (Source: Morgan Stanley, May 9, 2025)
- Manufacturing capacity, global supply chains and drug-launch readiness are becoming as important as the therapy itself.
- The winner of this deal will gain not only pipeline assets but also a strategic position in one of pharma’s next battlegrounds.
For Novo Nordisk, securing Metsera would reinforce its leadership in obesity drugs and help counter mounting competition from companies like Eli Lilly and Company. For Pfizer, the acquisition is a critical step to break into the obesity-drug market and offset pressures from patent expirations and declining legacy products.
What to Watch Next
- Pfizer’s next move remains closely watched, as investors anticipate whether the company will increase its bid beyond Novo’s latest offer, reportedly in the $10 billion range as of November 4.
- Regulatory and antitrust scrutiny is expected to intensify, given Novo Nordisk’s dominant position in the GLP-1 segment and the growing concerns over market competition.
- Industry observers are also focusing on how this potential deal could reshape global supply chains, manufacturing priorities, and the rollout strategy for next-generation obesity treatments.

Leave a Reply